Finanzen von Dynavax Technologies Corp (DVAX)DVAXDynavax Technologies Corp

Dynavax Technologies Corp (DVAX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is HEPLISAV-B, accounting for 94.8% of total sales, equivalent to $89.95M. Another important revenue stream is Other revenue. Understanding this composition is critical for investors evaluating how DVAX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Dynavax Technologies Corp maintains a gross margin of 84.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 22.42%, while the net margin is 28.38%. These profitability ratios, combined with a Return on Equity (ROE) of -7.14%, provide a clear picture of how effectively DVAX converts its operational activities into shareholder value.

In the context of the broader market, DVAX competes directly with industry leaders such as SNDX and ANIP. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, DVAX's gross margin of 84.82% stands against SNDX's 95.59% and ANIP's 54.97%. Such benchmarking helps identify whether Dynavax Technologies Corp is trading at a premium or discount relative to its financial performance.

- Latest reported quarter: 2025/Q3.

- Revenue: $94.876M, +17.67% YoY (solid top-line growth).

- Net income: $26.927M, +53.05% YoY (profitability accelerating).

- EPS: $0.20, +81.82% YoY (strong earnings leverage).

- Gross margin: 84.82%, +1.25% YoY (already high, improving further).